ESPERITE (ESP): EUR 500,000 of new funding provided by European Select Growth Opportunities Fund until March 2, 2018
Continuation of support to Esperite’s strategy, commercial activities and development of innovative technologies in the field of genetics and regenerative medicines.
Amsterdam, The Netherlands – 16 February 2018
As of today, EUR 5,010,000 of notes out of the total commitment amounting to EUR 9 million have been converted into shares and EUR 247,500 of warrants out of a total potential amount of EUR 4,050,000 have been exercised into shares by European Select Growth Opportunities Fund (the “Investor”), therefore strengthening the Group’s equity.
The Investor confirms its continuation of support to the development of Esperite’s commercial activities and development of innovative technologies in the field of genetics and regenerative medicine and Esperite’s strategy towards market development activities and has agreed to subscribe for a new tranche of EUR 250,000 today upon request of Esperite (the “15th Tranche”), although the conditions required under the financing agreement of up to EUR 13 million signed between Esperite and the Investor on March 8, 2017 (the “Agreement”) are not currently met, in consideration for an additional commitment fee to waive such conditions.
The Group expects to issue a total of EUR 500,000 of principal amount of notes with warrants attached before March 2, 2018. The 15th Tranche is issued pursuant to a request from Esperite dated February 15, 2018 to issue up to EUR 500,000 in two tranches of EUR 250,000 principal amount each (the “15th and 16th Tranches”) between today and March 2, 2018. The commitment of the Investor to subscribe to the 16th Tranche is subject to the fact that there will be EUR 100,000 or less of notes outstanding on this date.
The 15th Tranche is a private placement of 25 convertible notes with a principal amount of EUR 10,000 each, with 222,772 warrants attached. The notes and the warrants issued under the 16th, Tranche shall have the same characteristics as those described in the press release dated March 8, 2017.
As from March 2, 2018 or as soon as the 16th Tranche will have been issued, unless agreed otherwise between Esperite and the Investor, the initial terms and conditions of the Agreement will prevail again, including in particular the conditions for the delivery of a request by Esperite and the funding of a tranche by the Investor as described in the press release dated March 8, 2017.
ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.
To learn more about the ESPERITE group, or to book an interview with CEO Frederic Amar: +31 575 548 998 – email@example.com or visit the websites at www.esperite.com www.genoma.com and www.cryo-save.com.
This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).
With respect to Member States of the European Economic Area that have transposed European Directive 2003/71/EC of the European Parliament and European Council (as amended in particular by Directive 2010/73/EU to the extent that the said Directive has been transposed into each Member State of the European Economic Area), no action has been taken or will be taken to permit a public offering of the securities referred to in this press release requiring the publication of a prospectus in any Member State.
This press release and the information it contains do not, and will not, constitute an offer to subscribe for or sell, nor the solicitation of an offer to subscribe for or buy, securities of Esperite in the United States of America or any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), it being specified that the securities of Esperite have not been and will not be registered within the US Securities Act. Esperite does not intend to register securities or conduct a public offering in the United States of America.